Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Whitehawk Therapeutics ( (WHWK) ) just unveiled an update.
Whitehawk Therapeutics, Inc. held its annual meeting of stockholders on June 11, 2025, where 61% of the voting power was represented. During the meeting, three Class II directors were elected, executive compensation was approved on an advisory basis, and BDO USA, P.C. was ratified as the independent accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (WHWK) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Whitehawk Therapeutics stock, see the WHWK Stock Forecast page.
Spark’s Take on WHWK Stock
According to Spark, TipRanks’ AI Analyst, WHWK is a Neutral.
Whitehawk Therapeutics’ overall score reflects challenges in financial performance, with ongoing profitability and liquidity issues. Technical analysis provides a slightly positive short-term outlook, but long-term trends remain concerning. Valuation suggests the stock might be undervalued, presenting potential opportunities for investors.
To see Spark’s full report on WHWK stock, click here.
More about Whitehawk Therapeutics
Average Trading Volume: 133,615
Technical Sentiment Signal: Sell
Current Market Cap: $94.22M
For an in-depth examination of WHWK stock, go to TipRanks’ Overview page.